One-Day depression treatment? new trial puts accelerated TMS to the test
NCT ID NCT07369180
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a faster version of transcranial magnetic stimulation (TMS) can safely treat major depressive disorder. Instead of the usual 30 sessions over six weeks, participants receive three 19-minute sessions in a single day. The trial includes 37 adults aged 22-85 with drug-resistant depression, comparing active treatment to a sham procedure to measure changes in mood scores.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Transcranial Magnetic Stimulation (TMS) device
- What this could lead to
- If it works, this could offer a faster, more convenient treatment option for depression, reducing the need for daily visits over weeks.
- What could go wrong
- This is a small, early-phase trial with only 37 participants, so results may not apply broadly. The accelerated schedule might not be as effective or safe as the standard regimen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 37 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Mar 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Males or females aged 22-85. 2. Current diagnosis of major depressive disorder according to the criteria defined in the current Diagnosis and Statistical Manual of Mental Disorders (DSM-V) without psychotic features. The diagnosis of DSM-5 criteria-defined MDD will be made by a psychiatrist in light of a comprehensive psychiatric evaluation and other available clinical data. 3. Drug-resistant MDD (lack of improvement on antidepressant medication in the current episode, despite adequate dose and duration and adherence to treatment). 4. MADRS score \> 20 at baseline and immediately prior to the day of treatment. 5. Agrees to adhere to the study treatment and follow-up schedule. 6. Evidence of no change in AD medications or psychotherapy from 4 weeks prior to enrollment and participant's agreement not to request such changes through 2 weeks after study regimen treatment. 7. Fluent in English. Exclusion Criteria: 1. Any medical conditions that would preclude the use of rTMS to treat depression. 2. Any conditions that would prevent the ability to undergo MRI testing. 3. Pregnancy as determined by serum/urine pregnancy test 4. History of epilepsy, seizure(s), or a seizure disorder as determined by the principal investigator based on a medical history obtained from the patient and/or others authorized to provide such history, combined with a brief screening instrument. 5. Active substance abuse 6. Diagnosis of bipolar or psychotic disorder 7. Considered to be at moderate-high risk of suicide according to the C-SSRS assessment (i.e., Answers YES to Question 3 and NO to Question 6; or answers YES to Question 4, 5, or 6) 8. As determined by the Principal Investigator, subjects with cognitive impairment according to either the medical history obtained from the patient and/or a reliable secondary source, or the results of the Montreal Cognitive Assessment (MoCA) performed during screening.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
LGTC Group
Campbell, California, 95008, United States
-
LGTC Group
Sunnyvale, California, 94086, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an antipsychotic restore feelings in people with depression?
- Can intense brain zaps lift depression? scientists track blood flow in real time
- Can an ancient herbal capsule boost antidepressant power?
- Can talk therapy keep Esketamine's relief going?
- Can brisk walking boost antidepressant results?
- Scientists probe brain's reward system in mental illness